» Articles » PMID: 19252524

MiR-449a Targets HDAC-1 and Induces Growth Arrest in Prostate Cancer

Overview
Journal Oncogene
Date 2009 Mar 3
PMID 19252524
Citations 179
Authors
Affiliations
Soon will be listed here.
Abstract

Histone deacetylases (HDACs) are frequently overexpressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery. In this study, we investigated the expression and functional significance of miR-449a in prostate cancer cells. Using real-time PCR, we found that miR-449a is downregulated in prostate cancer tissues relative to patient-matched control tissue. Introduction of miR-449a into PC-3 prostate cancer cells resulted in cell-cycle arrest, apoptosis and a senescent-like phenotype. In silico analysis of 3'-UTR regions identified a number of genes involved in cell-cycle regulation as putative targets of miR-449a. Using a luciferase 3'-UTR reporter system, we established that HDAC-1 (histone deacetylase 1), a gene that is frequently overexpressed in many types of cancer, is a direct target of miR-449a. Further, our data indicate that miR-449a regulates cell growth and viability in part by repressing the expression of HDAC-1 in prostate cancer cells. Our findings provide new insight into the function of miRNA in regulating HDAC expression in normal versus cancerous tissue.

Citing Articles

Exploring the therapeutic potential of natural products in modulating miRNA networks in prostate cancer.

Mohammed O Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976718 DOI: 10.1007/s00210-025-03898-2.


Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis.

Zhou Y, Yao W, Chen S, Wang P, Fu J, Zhao J Front Pharmacol. 2025; 15():1483186.

PMID: 39845793 PMC: 11753231. DOI: 10.3389/fphar.2024.1483186.


HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.


MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.

Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgues O, Hernando C, Martinez M Cell Death Discov. 2024; 10(1):372.

PMID: 39174500 PMC: 11341569. DOI: 10.1038/s41420-024-02128-7.


The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.

Isachesku E, Braicu C, Pirlog R, Kocijancic A, Busuioc C, Pruteanu L Int J Mol Sci. 2023; 24(22).

PMID: 38003512 PMC: 10671451. DOI: 10.3390/ijms242216320.